Targets › CLDN18
43 programs from 39 companies in 81 trials: 40 Phase 1, 23 Phase 2, 18 Phase 3; Oncology, Gastroenterology; next expected readout Nov 2026.
Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). (UniProt, P56856)
Open in Phaseline: the race on CLDN18, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| LaNova Medicines Zhejiang | LM-302 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma; Malignant Neoplasms of Digestive Organs | Nov 2026 |
| AstraZeneca | AZD0901 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Gastric Cancer | Nov 2026 |
| Innovent Biologics (Suzhou) | IBI343 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Cancer; CLDN18.2 Positive; Locally Advanced Unresectable or Metastatic Solid Tumors … | Dec 2026 |
| Astellas | zolbetuximab Claudin-18 binding agent | CLDN18 | Phase 3 | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Pancreatic Cancer; Pharmacokinetics of Zolbetuximab; Metastatic Pancreatic Adenocarcinoma … | Dec 2026 |
| FutureGen Biopharmaceutical (Beijing) | M108 monoclonal antibody anti-CLDN18.2 monoclonal antibody | CLDN18 | Phase 3 | Locally Advanced Unresectable or Metastatic Gastric Cancer | Jan 2027 |
| Suzhou Immunofoco Biotechnology | IMC002 anti-CLDN18.2 CAR-T cell therapy | CLDN18 | Phase 3 | Gastric Adenocarcinoma | May 2027 |
| Biokin (Shanghai) Biopharmaceutical | BL-M05D1 anti-CLDN18.2 antibody | CLDN18 | Phase 3 | Gastric Cancer; Locally Advanced or Metastatic Solid Tumors | Jun 2027 |
| Shanghai Hengrui Pharmaceutical | SHR-A1904 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Cancer; CLDN18.2-positive Advanced Solid Tumor | Sep 2027 |
| Antengene Biologics | ATG-022 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma; Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced/Metastatic Solid Tumors | Sep 2027 |
| Shanghai Junshi Bioscience Co., Ltd. | JS107 for Injection anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumors | Oct 2027 |
| Astellas | ASP2138 Bispecific antibody binding CLDN18.2 on tumor cells and CD3E on T cells | CD3E, CLDN18 | Phase 3 | Gastric Adenocarcinoma; Pancreatic Ductal Adenocarcinoma | Jan 2028 |
| Qilu Pharmaceutical | QLS31905 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Cancer | Sep 2028 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | LM-302 Injection anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Adenocarcinoma | Oct 2028 |
| NingBo Junyan Hongshi Biosciences | JS107 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Gastric Adenocarcinoma | Jan 2029 |
| Shanghai Zhongshan Hospital | LM-302 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 2 | Gastric or Gastroesophageal Junction Adenocarcinoma; Biliary Tract Cancer | Dec 2026 |
| I-Mab Biopharma US | TJ033721 (givastomig) anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 2 | Solid Tumor | Dec 2026 |
| First Affiliated Hospital of Ningbo University | Zebtorizumab anti-CLDN18 monoclonal antibody | CLDN18 | Phase 2 | DLBCL | Dec 2026 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | benmelstobart Anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 2 | Unresectable Hepatocellular Carcinoma | Dec 2026 |
| Ruijin Hospital | LM-302 anti-CLDN18.2 antibody | CLDN18 | Phase 2 | Gastric Cancer Stage IV; Gastric or Esophagogastric Junction Adenocarcinoma | Jan 2027 |
| First Affiliated Hospital of Zhejiang University | Benmelstobart Anti-CLDN18.2 monoclonal antibody | CLDN18 | Phase 2 | HR+/HER2- Breast Cancer | Apr 2027 |
| The First Affiliated Hospital with Nanjing Medical University | Zebetuzumab Claudin-18.2 (CLDN18.2) monoclonal antibody | CLDN18 | Phase 2 | Marginal Zone Lymphoma(MZL) | Jun 2028 |
| Astellas | ASP546C (XNW27011) anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Pancreatic Adenocarcinoma Metastatic; Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | Dec 2026 |
| L & L Bio Co., Ltd., Ningbo, China | LB4330 anti-claudin18.2/IL-10 fusion protein | CLDN18, IL10 | Phase 1 | Solid Tumor | Dec 2026 |
| CARsgen Therapeutics | CT041 autologous CAR T-cell injection anti-CLDN18.2 chimeric antigen receptor T-cell | CLDN18 | Phase 1 | Pancreatic Cancer; Gastric Cancer; Gastric Adenocarcinoma | Dec 2026 |
| Hangzhou Sumgen Biotech | SG1906 anti-CLDN18.2 antibody or antibody-drug conjugate | CLDN18 | Phase 1 | Locally Advanced Unresectable or Metastatic Solid Tumors | Feb 2027 |
| Beijing Biotech | EB-DT-CAR-NK Dual-target CLDN18.2/HER2 CAR-NK cells | CLDN18, ERBB2 | Phase 1 | Advanced Gastric Adenocarcinoma | Mar 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Claudin18.2-targeted CAR-DCs anti-CLDN18.2 CAR-dendritic cell therapy | CLDN18 | Phase 1 | Colorectal Neoplasia | Apr 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Claudin18.2-targeted CAR-T Cells anti-CLDN18.2 CAR-T cells | CLDN18 | Phase 1 | Colorectal Neoplasia | Apr 2027 |
| Bolt Biotherapeutics | BDC-4182 Anti-CLDN18.2 monoclonal antibody conjugated to TLR7/8 dual agonist | CLDN18, TLR7, TLR8 | Phase 1 | Gastric Cancer Adenocarcinoma Metastatic | May 2027 |
| Zhejiang Cancer Hospital | IBI343 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Advanced Pancreatic Cancer | Jun 2027 |
| Peking University | KD-496 Dual CAR-T cell therapy targeting NKG2D ligands and CLDN18.2 | NKG2D, CLDN18 | Phase 1 | Gastric Cancer | Jun 2027 |
| Transcenta Therapeutics (Hangzhou) | TST001 Anti-CLDN18.2 monoclonal antibody | CLDN18 | Phase 1 | Advanced Cancer | Jun 2027 |
| Anova Innovation | ANO31905 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Pancreatic Cancer | Aug 2027 |
| Essen Biotech | Mesothelin and Claudin 18.2 CAR-T cells Dual-target CAR-T cells targeting Mesothelin and Claudin 18.2 | MSLN, CLDN18 | Phase 1 | Pancreatic Cancer | Dec 2027 |
| Legend Biotech USA | LB1908 anti-CLDN18.2 CAR-T cell therapy | CLDN18 | Phase 1 | Gastric Cancer | Dec 2027 |
| Phanes Therapeutics | Spevatamig (PT886) Bispecific antibody targeting Claudin 18.2 and CD47 | CLDN18, CD47 | Phase 1 | Gastric or Gastroesophageal Junction Adenocarcinoma | Dec 2027 |
| Dong-A ST | DA-3501 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Gastric (Stomach) Cancer | Feb 2028 |
| Shanghai Institute Of Biological Products | SIBP-A18 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Solid Tumor Malignancy | May 2028 |
| Sichuan Kelun-Biotech Biopharmaceutical | SKB315 for injection anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Advanced Solid Tumors | Jun 2028 |
| AstraZeneca | AZD5863 T cell-engaging bi-specific antibody targeting CLDN18.2 and CD3 | CLDN18, CD3E | Phase 1 | Gastric Cancer | Mar 2029 |
| LigaChem Biosciences | LCB02A anti-CLDN18.2 antibody-drug conjugate with topoisomerase I inhibitor payload | CLDN18 | Phase 1 | Advanced Solid Tumors | Feb 2030 |
| Sichuan University | Dual-targeting CLDN18.2 and PD-L1 CAR-T cells Dual-targeting CAR-T cells against CLDN18.2 and PD-L1 | CLDN18, CD274 | Phase 1 | Advanced Solid Tumor | – |
| RemeGen | RC118-ADC Anti-CLDN18.2 antibody-drug conjugate with microtubule inhibitor payload | CLDN18 | Phase 1 | Advanced Solid Tumor | – |
Gastric Cancer (11) Pancreatic Cancer (6) Gastric Adenocarcinoma (5) Advanced Solid Tumors (3) Gastric or Gastroesophageal Junction Adenocarcinoma (3) Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer (3) Solid Tumor (3) Advanced Solid Tumor (2) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2) Advanced Cancer (2) Gastric Cancer Stage IV (2) Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (2)
small molecule (17), mixed (15), antibody (5), other (3), protein or peptide (2)
Astellas (3) AstraZeneca (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (2) RemeGen (1) Shanghai Institute Of Biological Products (1) Peking University (1) Beijing Biotech (1) Sichuan Kelun-Biotech Biopharmaceutical (1) Biokin (Shanghai) Biopharmaceutical (1) Shanghai Zhongshan Hospital (1) Shanghai Junshi Bioscience Co., Ltd. (1) Transcenta Therapeutics (Hangzhou) (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Shanghai Hengrui Pharmaceutical (1) Ruijin Hospital (1) Innovent Biologics (Suzhou) (1) Antengene Biologics (1) The First Affiliated Hospital with Nanjing Medical University (1) Suzhou Immunofoco Biotechnology (1) Anova Innovation (1)
CD3E (2) NKG2D (1) ERBB2 (1) CD274 (1) TLR7 (1) TLR8 (1) MSLN (1) CD47 (1) IL10 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.